江蘇吳中(600200.SH):擬對全資子公司吳中醫藥增資3.4億元
格隆匯1月14日丨江蘇吳中(600200.SH)公佈,江蘇吳中醫藥集團有限公司(以下簡稱“吳中醫藥”)為公司的全資子公司,因業務發展需要,公司擬以現金形式對吳中醫藥進行增資,擬增資金額為3.4億元人民幣。本次增資完成後,吳中醫藥的註冊資本由4億元增加至7.4億元。
本次增資的目的主要為滿足吳中醫藥的業務經營需要。本次增資完成後,吳中醫藥仍為公司全資子公司。本次增資有利於改善吳中醫藥財務結構,促進核心醫藥業務進一步快速發展,符合公司整體發展戰略,符合公司和全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.